References

1. Chen YL, Eriksson S, Chang ZF. The regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem. 2010 Jun 16. [Epub ahead of print]

2. He E, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma. Nucleosides Nucleotides Nucleic Acids. 2010, 29: p. 352-8.

3. Li Z, Wang Y et al. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Anticancer Res. 2010, 4: p. 1295-9.

4. Li Z, Wang Y et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010, 19: p. 313-8.

5. Shintani M, et al. Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. Oncol Rep. 2010, 23: p. 1345-50.

6. Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010 Apr 1. [Epub ahead of print]

7. Pan ZL, et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J Cancer Res Clin Oncol. 2010, 136: p. 1193-9.

8. Luo P et al. The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells. Pathol Oncol Res. 2010, 16: p. 277-83.

9. Barwick T et al. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009, 30: p. 908-17.

10. Gasparri F, et al. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell Biol. 2009, 88: p. 779-85.

11. Brockenbrough JS et al. Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem. 2009, 57: p. 1087-97.

12. Xu W, et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol. 2009, 90: p. 205-11.

13. Carlsson L, Larsson A, Lindman H. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer. Ups J Med Sci. 2009, 114: p. 116-20.

14. Luo P, et al. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev. 2009, 18: p. 220-4.

15. Chen Z, et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res. 2008, 28: p. 3897-907.

16. Von Euler HP, et al. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity–evaluation of a new, fully automated non-radiometric assay. Int J Oncol. 2009, 34: p. 505-10.

17. van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008, 14: p. 3326-339.

18. Direcks WG, et al. 18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer. 2008, 99: p. 481-7.

19. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008, 49 Suppl 2: p. 64S-80S.

20. Barth RF, et al. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. Proc Natl Acad Sci U S A. 2008, 105: p. 17493-17497

21. Topolcan O, et al. The role of thymidine kinase in cancer diceases. Expert Opin. Med Diagn. 2008, 2:p. 129-14

22. Votava T, et al. Changes of serum thymidine kinase in children with acute leukemia. Anticancer Res. 2007, 27:1925-1928.

23. Svobodova S, et al. Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Res. 2007, 27: p. 1907-1909

24. Matthews C, et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol. 2006, 77: p. 309-317.

25. He, Q, Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2006, 26: p. 4753-4759

26. Zhang, J, et al. Thymidine kinase 1: A proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncology Reports, 2006, 15: p. 455-461.

27. He, Q, et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncology Reports, 2005, 14: p. 1013-1019.

28. Mao Y, et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncology Reports, 2005, 13: p. 837-846.

29. Welin M, et al. Structures of thymidine kinase 1 of human and mycoplasma origin. 2004, Proc. Natl. Acad. Sci. USA 102: p.17970-17975.

30. Öhrvik A, et al. Sensitive nonradiometric method for determining Thymidine kinase 1 activity. 2004 Clin Chem 50: p.1597-1606.

31. He, Q, et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. 2004 Internt. J. Oncology 25: p. 945-953.

32. Wu, C., et al., Production and characterisation of a novel chicken antibody raised against C-terminal peptide from human thymidine kinase 1. Journal of Immunological Methods, 2003. 277: p. 157-169.

33. Al-Madhoun, A.S., W. Tjarks, and S. Eriksson, The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini-Reviews in Medicinal Chemistry, 2004. 4: p. 341-350.

34. He, Q., et al., Cytosolic thymidine kinase is a specific histopathologic tumor marker for breast carcinomas. International Journal of Oncology, 2004. 25: p. 945-953.

35. Eriksson, S., et al., Structure and function of cellular deoxyribonucleoside kinases. Cellular and Molecular Life Sciences, 2002. 59: p. 1327-1346.

36. He, Q., et al., X-irradiation effects on thymidine kinase (TK): II. The significance of deoxythymidine triphosphate for inhibition of TK1 activity. Cell Proliferation, 2002. 35: p. 83-92.

37. He, Q., et al., X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells. Cell Proliferation, 2002. 35: p. 69-81.

38. Zou, L., et al., The half-life of thymidine kinase 1 in serum mesured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. The International Journal of Biological Markers, 2002. 17: p. 135-140.

39. Mao, Y., et al., A comparative study: Immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Investigation, 2002. 20: p. 922-931.

40. O´Neill KL. et al. Thymidine kinase: diagnostic and prognostic potential. Expert Rev. Mol. Diagn. 2001, 1:p.428-433

41. Johansson, K., et al., Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. Nature Structural Biology, 2001. 8: p. 616-620.

42. Jacobsson, B., F. Albertioni, and S. Eriksson,Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells. Cancer Letters, 2001. 165: p. 195-200.

43. Wang, N., et al., Investigation on cell proliferation with a new antibody against thymidine kinase 1. Analytical and Cellular Pathology, 2001. 23: p. 11-19.

44. Wu, J., et al., A new cell proliferating marker: Cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Research, 2000. 20: p. 4815-4820.

45. Wang, L. and S. Eriksson, Cloning and characterization of full-lenght mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. Biochemical Journal, 2000. 351: p. 469-476.

46. He, Q., et al., The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. The International Journal of Biological Markers, 2000. 15: p. 139-146.

47. Wang, L., et al., Human thymidine kinase 2: Molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Letters, 1999. 443: p. 170-174.

48. He, Q., et al., Characterization of a peptide antibody against C-terminal part of a human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. European Journal of Cell Biology, 1996. 70: p. 117-124.

49. He, Q., et al., Existence of phosphorylated and dephosphorylated forms of cytosolic thymidine kinase (TK1). Biochimica et Biophysica Acta, 1996. 1289: p. 25-30.

50. He, Q., S. Skog, and B. Tribukait, Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumours. Cell Proliferation, 1991. 24: p. 3-14.